Generated by AI
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare and underserved diseases. Eton Pharmaceuticals, Inc. offers a commercial portfolio that includes therapies for adrenal insufficiency, severe primary IGF-1 deficiency, Wilson disease, phenylketonuria, homocystinuria, tyrosinemia type 1, and central diabetes insipidus, along with prescription products such as oral suspensions, injectable formulations, and oral solutions. The company also works across pediatric and adult care settings, supporting medications used in endocrine, metabolic, and other niche therapeutic areas. Based in Deer Park, Illinois, Eton Pharmaceuticals, Inc. plays a focused role in the rare-disease market by bringing specialized medicines to patients and healthcare providers through a mix of in-licensed products, commercial launches, and targeted product development.
Website21925 W. Field Parkway
Deer Park, IL, 60010-7278
United States
The latest articles about ETON.
Robust growth fuels Eton Pharmaceuticals, but the biotech faces key test.
Summary of Oct 14's posts. Generated by AI.
Summary of Feb 25's posts. Generated by AI.
Summary of Aug 14's posts. Generated by AI.
Investors talking about ETON also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.